Advertisement

Rheumatology International

, Volume 33, Issue 10, pp 2687–2689 | Cite as

Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis

  • Emilio BesadaEmail author
  • Rune Johan Njålla
  • Johannes C. Nossent
Short Communication

Abstract

We report a case of visceral leishmaniasis in a patient from northern Norway with psoriatic arthritis treated with a combination of etanercept and methotrexate. The patient resided extensively in southern Spain, a zone endemic for leishmania.

Keywords

Visceral leishmaniasis Etanercept Psoriasis arthritis Tumor necrosis factor-alpha Inhibitors Opportunistic infection 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ready PD (2010) Leishmaniasis emergence in Europe. Euro Surveill 15(10):19505PubMedGoogle Scholar
  2. 2.
    Moral L, Rubio EM, Moya M (2002) A leishmanin skin test survey in the human population of l’Alacantí region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans R Soc Trop Med Hyg 96:129–132PubMedCrossRefGoogle Scholar
  3. 3.
    Marty P, Izri A, Ozon C, Haas P, Rosenthal E, Del Giudice P et al (2007) A century of leishmaniasis in Alpes-Maritimes, France. Ann Trop Med Parasitol 101:563–574PubMedGoogle Scholar
  4. 4.
    Erre GL, Mesina P, Tonelli N, Passiu G (2010) Visceral leishmaniasis among immunosuppressed patients with rheumatic diseases. Clin Exp Rheumatol 28:590–591PubMedGoogle Scholar
  5. 5.
    Marty P, Pomares-Estran C, Hasseine L, Delaunay P, Haas H, Rosenthal E (2009) Leishmaniasis in France: an update. Arch Pediatr 16(Suppl 2):S96–S100PubMedCrossRefGoogle Scholar
  6. 6.
    Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV (2009) Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. Emerg Infect Dis 15:956–959PubMedCrossRefGoogle Scholar
  7. 7.
    Malik ANJ, John L, Bryceson ADM, Lockwood DNJ (2006) Changing pattern of visceral leishmaniasis, United Kingdom, 1985–2004. Emerg Infect Dis 12:1257–1259PubMedCrossRefGoogle Scholar
  8. 8.
    De Leonardis F, Govoni M, Lo Monaco A, Trotta F (2009) Visceral leishmaniasis and anti-TNF-α therapy: case report and literature review. Clin Exp Rheumatol 27:503–506PubMedGoogle Scholar
  9. 9.
    Sakkas LI, Boulbou M, Kyriakou D, Makri I, Sinani C, Germenis A et al (2008) Immunological features of visceral leishmaniasis may mimic systemic lupus erythematosus. Clin Biochem 41:65–68PubMedCrossRefGoogle Scholar
  10. 10.
    Castellino G, Govoni M, Lo Monaco A, Montecucco C, Colombo F, Trotta F (2004) Visceral leishmaniasis complicating a connective tissue disease: three case reports from Italy. Lupus 13:201–203PubMedCrossRefGoogle Scholar
  11. 11.
    Viana RB, Neiva CL, Dias AF, do Rosario e Souza EF, de Padua PM (2010) Felty’s syndrome and Kala-azar: a challenge for the rheumatologist. Rev Bras Rheumatol 50:710–715CrossRefGoogle Scholar
  12. 12.
    Ahlin E, Elshafei A, Nur M, El Safi SH, Ronnelid J, Elghazali G (2011) Anti-citrullinated peptide antibodies and rheumatoid factor in Sudanese patients with Leishmania Donovani infection. Rev Bras Reumatol 51:572–586CrossRefGoogle Scholar
  13. 13.
    Rizos E, Dimos G, Liberopoulos EN, Elisaf MS, Drosos AA (2005) Cryoglobulinemic purpura in visceral leishmaniasis. Rheumatol Int 25:469–471PubMedCrossRefGoogle Scholar
  14. 14.
    Skram MK, Bjering S, Hermansen NO, Dini L, Hellebostad M (2011) En 15 gammel måneder jenta med feber og pancytopeni. Tidsskr Nor Legeforen 31:2482–2486CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Emilio Besada
    • 1
    Email author
  • Rune Johan Njålla
    • 2
  • Johannes C. Nossent
    • 1
  1. 1.University North NorwayTromsöNorway
  2. 2.Hospital of NordlandBodøNorway

Personalised recommendations